The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Published:2023-02-22 Issue:4 Volume:24 Page:511-521
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Jiao Ruoyang¹,Lin Chu¹^ORCID,Bai Shuzhen¹,Cai Xiaoling¹,Hu Suiyuan¹,Lv Fang¹,Yang Wenjia¹,Zhu Xingyun¹,Ji Linong¹^ORCID

Affiliation:

1. Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, Hebei, China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Beijing Municipality

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2181693

Reference45 articles.

1. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis

2. Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis

3. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

4. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

5. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects